PD-L1 and VEGF-A

Class

PD-L1 x VEGF-A bispecific antibody

Pathway

PD-1/PD-L1 immune checkpoint blockade combined with VEGF-mediated angiogenesis inhibition

PD-L1 is a protein expressed on tumor cells and certain immune cells that binds the receptor PD-1 on T cells, delivering an inhibitory signal that dampens T-cell activity and allows tumors to evade immune surveillance. VEGF-A is a growth factor that drives angiogenesis, the formation of new blood vessels, which tumors rely on for nutrient supply and which can also foster an immunosuppressive microenvironment by impairing T-cell infiltration and favoring other inhibitory immune cell populations. A bispecific antibody that simultaneously blocks PD-L1 and neutralizes VEGF-A combines two complementary mechanisms into one molecule: it releases the inhibitory brake on T-cell mediated tumor killing while also compromising the vascular support and immunosuppressive conditions that tumors depend on. Uniting both targets in a single molecule allows preferential engagement where PD-L1 and VEGF-A are co-expressed, such as within tumor tissue, potentially concentrating activity in diseased tissue relative to administering two separate agents. This mechanism is broadly relevant across solid tumors where immune evasion and neovascularization jointly sustain tumor growth, reflecting a rationale of pairing checkpoint blockade with anti-angiogenic therapy for more comprehensive modulation of the tumor microenvironment than either approach alone.